Tempus Q4 Revenue Soars 83% to $367M, Guides $1.59B for 2026
Tempus delivered Q4 2025 revenue of $367.2 million, up 83% year-over-year, and full-year revenue of $1.2 billion while issuing 2026 guidance for $1.59 billion revenue with $65 million in adjusted EBITDA, marking its first positive adjusted profitability. The platform serves over 50% of U.S. oncologists and is expanding into cardiovascular diagnostics.
1. Q4 2025 Performance
Tempus reported fourth quarter revenue of $367.2 million, an 83% increase year-over-year driven by growth in diagnostics unit placements and AI-driven data services.
2. Full-Year Results and Guidance
For full-year 2025, Tempus achieved $1.2 billion in revenue and provided 2026 guidance of $1.59 billion in revenue with approximately $65 million in adjusted EBITDA, projecting its first year of positive adjusted profitability.
3. Platform Expansion
The company's integrated platform of genomic sequencing, clinical data analytics and AI insights serves over 50% of U.S. oncologists and is expanding data licensing and clinical trial matching into cardiovascular diagnostics.
4. Strategic Collaboration with Merck
Tempus announced a strategic collaboration agreement with Merck to accelerate AI-driven precision medicine, aiming to enhance its oncology and cardiology offerings through combined research and development efforts.